The information on this site is intended for healthcare professionals.
Over the past 25 years, daily hGH has been optimized for treating GHD. Daily injections can be difficult for children and families. Research shows two out of three patients miss more than one injection on average per week.1 Poor compliance with daily hGH therapy is associated with reduced height velocity and impaired quality of life.1
The once-weekly TransCon Growth Hormone being studied in the heiGHt Trial contains somatropin, the same active ingredient in daily hGH products, in a sustained-release formulation. It is also the only long-acting growth hormone in development that delivers native hGH. The hope is that fewer injections may be preferable to children and their families, so fewer doses may be missed. In turn, this may lead to better treatment outcomes.
TransCon Growth Hormone is a sustained-release prodrug that predictably delivers native hGH in the same therapeutic range as approved daily hGH products.
Six-month, multi-center, randomized, open-label, Phase 2 study (n=53) investigating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of once-weekly TransCon Growth Hormone in treatment-naïve pre-pubertal children with GHD. This study compared three dose levels of once-weekly TransCon Growth Hormone (0.14, 0.21, and 0.30 mg/kg/week) vs. the active daily hGH control Genotropin (0.21 mg/kg/week administered as a daily injection).
TransCon Growth Hormone is an investigational product in clinical studies for use in children with GHD. TransCon Growth Hormone has not been approved by any regulatory agency for this investigational use, and, as such, may not be safe or effective.
The heiGHt Trial is sponsored by Ascendis Pharma Endocrinology Division A/S; a company in the Ascendis Pharma group.
1. Cutfield WS, Derraik JGB, Gunn AJ, et al. PLoS One. 2011;6(1):e16223.
2. Chatelain P, Malievsky O, Radziuk K, Senatorova G, Beckert M. Poster presented at: 54th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE); October 1-3, 2015; Barcelona, Spain.
3. Chatelain P et al. Oral presentation at: 98th Annual Meeting of the Endocrine Society (ENDO); April 1-4, 2016; Boston, Massachusetts.
4. European Medicines Agency. Assessment report Somatropin Biopartners EMEA/H/C/002196/0000. May 30, 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002196/WC500148755.pdf. Accessed March 24, 2016.